0564539-A1 cites 2 patents.

This invention provides improved methods for producing high titers of recombinant viral vectors by culturing producer cells in a hollow fiber bioreactor. The titer of virus in the extra fiber space (EFS) of the hollow fiber bioreactor is sufficient to transduce target cells at a multiplicity of infection sufficient to render the transduced target cells useful for genetic therapy. In a preferred embodiment, target cells are transduced with the EFS medium from a hollow fiber bioreactor in which a producer cell line, which releases packaged retroviral vectors into the EFS, has been cultured. Lymphocytes derived from an adenosine deaminase (ADA)-deficient individual that have been transduced with EFS medium that contains retroviral vectors that include RNA that encodes ADA, express ADA at a rate comparable to that of cells from an individual who does not have ADA deficiency.

Title
Sustained and continuous production of high titers of recombinant viral vectors and transduced target cells for use in gene therapy.
Application Number
EP19920902297 19911210
Publication Number
0564539 (A1)
Application Date
December 10, 1991
Publication Date
October 13, 1993
Inventor
Blaese R Michael
US
Knazek Richard A
US
Culver Kenneth W
US
Assignee
Cellco
US
Us Commerce
US
IPC
C12N 07/02
C12N 05/06
C12N 05/00
C12M 03/00
C12N 15/867
C12N 15/09
C12N 09/78
C12N 09/26
C12N 07/00
C12N 05/10
C12M 03/06
C12M 01/00
C12N 15/867
C12N 15/09
C12N 09/78
C12N 09/26
C12N 07/00
C12N 05/10
C12M 03/06
C12M 01/00
View Original Source Download PDF